Literature DB >> 29764912

Mitochondrial PITRM1 peptidase loss-of-function in childhood cerebellar atrophy.

Yeshaya Langer1, Adi Aran2, Suleyman Gulsuner3, Bassam Abu Libdeh4, Paul Renbaum5, Dario Brunetti6,7, Pedro-Filipe Teixeira8, Tom Walsh3, Sharon Zeligson5, Roberta Ruotolo9, Rachel Beeri5, Imad Dweikat4, Maher Shahrour4, Ariella Weinberg-Shukron5, Fouad Zahdeh5, Enrico Baruffini9, Elzbieta Glaser8, Mary-Claire King3, Ephrat Levy-Lahad10, Massimo Zeviani6, Reeval Segel11.   

Abstract

OBJECTIVE: To identify the genetic basis of a childhood-onset syndrome of variable severity characterised by progressive spinocerebellar ataxia, mental retardation, psychotic episodes and cerebellar atrophy.
METHODS: Identification of the underlying mutations by whole exome and whole genome sequencing. Consequences were examined in patients' cells and in yeast.
RESULTS: Two brothers from a consanguineous Palestinian family presented with progressive spinocerebellar ataxia, mental retardation and psychotic episodes. Serial brain imaging showed severe progressive cerebellar atrophy. Whole exome sequencing revealed a novel mutation: pitrilysin metallopeptidase 1 (PITRM1) c.2795C>T, p.T931M, homozygous in the affected children and resulting in 95% reduction in PITRM1 protein. Whole genome sequencing revealed a chromosome X structural rearrangement that also segregated with the disease. Independently, two siblings from a second Palestinian family presented with similar, somewhat milder symptoms and the same PITRM1 mutation on a shared haplotype. PITRM1T931M carrier frequency was 0.027 (3/110) in the village of the first family evaluated, and 0/300 among Palestinians from other locales. PITRM1 is a mitochondrial matrix enzyme that degrades 10-65 amino acid oligopeptides, including the mitochondrial fraction of amyloid-beta peptide. Analysis of peptide cleavage activity by the PITRM1T931M protein revealed a significant decrease in the degradation capacity specifically of peptides ≥40 amino acids.
CONCLUSION: PITRM1T931M results in childhood-onset recessive cerebellar pathology. Severity of PITRM1-related disease may be affected by the degree of impairment in cleavage of mitochondrial long peptides. Disruption and deletion of X linked regulatory segments may also contribute to severity. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  PITML; cerebellar atrophy; mitochondria; next generation sequencing; whole exome sequencing

Mesh:

Substances:

Year:  2018        PMID: 29764912     DOI: 10.1136/jmedgenet-2018-105330

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  10 in total

Review 1.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

2.  [Progressive psychomotor regression for 2.5 years in a boy aged 5 years].

Authors:  Mao-Qiang Tian; Xiao-Xi Chen; Lei Li; Chang-Hui Lang; Juan Li; Jing Chen; Xiao-Hua Yu; Xiao-Mei Shu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-06-15

3.  Gain of PITRM1 peptidase in cortical neurons affords protection of mitochondrial and synaptic function in an advanced age mouse model of Alzheimer's disease.

Authors:  Fang Du; Qing Yu; Shijun Yan; Zhihua Zhang; Jhansi Rani Vangavaragu; Doris Chen; Shi Fang Yan; Shirley ShiDu Yan
Journal:  Aging Cell       Date:  2021-05-05       Impact factor: 9.304

Review 4.  Some Molecular and Cellular Stress Mechanisms Associated with Neurodegenerative Diseases and Atherosclerosis.

Authors:  Margarita A Sazonova; Vasily V Sinyov; Anastasia I Ryzhkova; Marina D Sazonova; Tatiana V Kirichenko; Victoria A Khotina; Zukhra B Khasanova; Natalya A Doroschuk; Vasily P Karagodin; Alexander N Orekhov; Igor A Sobenin
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

Review 5.  The Power of Yeast in Modelling Human Nuclear Mutations Associated with Mitochondrial Diseases.

Authors:  Camilla Ceccatelli Berti; Giulia di Punzio; Cristina Dallabona; Enrico Baruffini; Paola Goffrini; Tiziana Lodi; Claudia Donnini
Journal:  Genes (Basel)       Date:  2021-02-20       Impact factor: 4.096

6.  In-frame deletion in canine PITRM1 is associated with a severe early-onset epilepsy, mitochondrial dysfunction and neurodegeneration.

Authors:  Marjo K Hytönen; Riika Sarviaho; Christopher B Jackson; Pernilla Syrjä; Tarja Jokinen; Kaspar Matiasek; Marco Rosati; Cristina Dallabona; Enrico Baruffini; Ileana Quintero; Meharji Arumilli; Geoffray Monteuuis; Jonas Donner; Marjukka Anttila; Anu Suomalainen; Laurence A Bindoff; Hannes Lohi
Journal:  Hum Genet       Date:  2021-04-09       Impact factor: 4.132

Review 7.  Mitochondrial Neurodegeneration.

Authors:  Massimo Zeviani; Carlo Viscomi
Journal:  Cells       Date:  2022-02-11       Impact factor: 6.600

8.  Structural basis for the mechanisms of human presequence protease conformational switch and substrate recognition.

Authors:  Wenguang G Liang; Juwina Wijaya; Hui Wei; Alex J Noble; Jordan M Mancl; Swansea Mo; David Lee; John V Lin King; Man Pan; Chang Liu; Carla M Koehler; Minglei Zhao; Clinton S Potter; Bridget Carragher; Sheng Li; Wei-Jen Tang
Journal:  Nat Commun       Date:  2022-04-05       Impact factor: 17.694

9.  DELE1 tracks perturbed protein import and processing in human mitochondria.

Authors:  Evelyn Fessler; Luisa Krumwiede; Lucas T Jae
Journal:  Nat Commun       Date:  2022-04-06       Impact factor: 14.919

10.  Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer's disease-like pathology in human cerebral organoids.

Authors:  María José Pérez; Dina Ivanyuk; Vasiliki Panagiotakopoulou; Gabriele Di Napoli; Stefanie Kalb; Dario Brunetti; Rawaa Al-Shaana; Stephan A Kaeser; Sabine Anne-Kristin Fraschka; Mathias Jucker; Massimo Zeviani; Carlo Viscomi; Michela Deleidi
Journal:  Mol Psychiatry       Date:  2020-07-07       Impact factor: 13.437

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.